We're where the business of medicine gets answers. An independent news media organization covering biotech, pharma, science, policy, finance, venture capital and markets, and how they drive the life sciences industry. Read us at www.endpts.com.
Endpoints News
Loading...
Sciwind has licensed its GLP-1 obesity drug to Pfizer and Verdiva Bio, but the Chinese biotech says more partnership deals are on the table.
GSK paid $10.6B for Nuvalent, timing the deal to capitalize on a share dip triggered by disappointing ASCO data.
WuXi AppTec is suing the Pentagon to get off a China military-linked company list — a designation that would subject it to Biosecure Act restrictions on federal contracts.
Takeda's plaque psoriasis pill tops Sotyktu in a direct Phase 3 comparison.
endpoints.news/takeda-plaqu...
In this week's Peer Review: Novo Nordisk's M&A chief John McDonald joins Forbion as an operating partner, and Perrigo ousts CEO Patrick Lockwood-Taylor over a code of conduct violation.
Catch up on all of his coverage here: endpoints.news/ceo-pay-life...
Biopharma executives collected some unusual perks in 2025. It's part of @andrewedunn.bsky.social's annual compensation series for @endpts.com, which also covers top-paid CEOs, employee pay and the largest golden parachutes from recent M&A deals.
Biopharma's 10 highest-paid scientists and doctors in 2025, ranked.
endpoints.news/biopharma-pa...
Amgen is fighting to keep Tavneos on the market, pushing back against an FDA withdrawal proposal tied to alleged clinical trial misconduct at its subsidiary ChemoCentryx.
Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth keeping on the market.
Thank you @endpts.com for sharing the story about Grace Science, so close to bringing gene therapy to patients with NGly1 disease, hoping for some regulatory flexibility.
endpoints.news/grace-scienc...
Endpoints News
Endpoints News
Endpoints News
Endpoints News
Grace Science CEO Matt Wilsey says FDA demands could kill its gene therapy for the rare and fatal NGLY1 deficiency by September without new funding or a regulatory break.
Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study.
The Dutch investment firm has scooped up Novo Nordisk’s head of M&A John McDonald as operating partner of business development and M&A.
endpoints.news
In 2025, companies provided CEOs with everything from cars to private jet trips, from medical license renewals to parking, and from housing to “limited disaster relief support.”
